Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
What if one of the most promising natural compounds for mood support has been sitting quietly in your cells this whole time — and the strongest clue to its importance came not from studying it directly, but from watching what happens when certain medications deliberately deplete it?
That’s the curious story of inositol. It doesn’t have the marketing budget of omega-3. It doesn’t have the cultural cachet of St John’s wort. But buried in the research on bipolar disorder, depression, and the side effects of mood-stabilising drugs, there’s a genuinely interesting picture emerging — one that deserves a clear-eyed look. Our Vitacuity database returned 15 papers on this topic, and what follows is an honest account of what they show, what they don’t, and what a sensible person might actually do with this information.
Inositol is a naturally occurring sugar alcohol — technically a carbocyclic polyol — that plays a critical role in how your brain cells communicate. Think of it as part of the internal messaging system inside neurons. When a neurotransmitter (like serotonin) binds to the outside of a brain cell, it triggers a cascade of signals *inside* the cell. Inositol is a key component of that cascade.
Here’s where it gets interesting. Two of the most widely used mood-stabilising medications — lithium and valproic acid (VPA) — appear to work, at least in part, by *depleting* inositol in the central nervous system [2]. This is known as the “inositol depletion hypothesis” of mood stabilisation. The thinking is that in conditions like bipolar disorder, certain inositol-dependent signalling pathways may be overactive, and bringing inositol levels down helps recalibrate that [12].
The catch? Lithium and valproic acid don’t just deplete inositol in the brain — they do it throughout the body, including peripheral tissues. And that peripheral depletion is thought to drive a significant number of the unpleasant side effects these drugs are known for: thyroid disruption, metabolic changes, weight gain [1, 2].
There are two main forms of inositol you’ll encounter in the research: *myo-inositol* (the most abundant form, found throughout the body) and *d-chiro-inositol* (found in lower concentrations but important in metabolic function). The research suggests these two forms work best together, and a specific ratio — 80 parts myo-inositol to 1 part d-chiro-inositol — reflects the natural physiological balance in the body [1, 2].
Evidence grade: Promising — some human clinical data, but small samples and the mechanism is still being confirmed.
The inositol depletion hypothesis gives us a compelling framework for understanding both the therapeutic effects of lithium and VPA *and* their side effects [12]. Research published in *European Review for Medical and Pharmacological Sciences* in 2021 reviewed the literature on this topic and concluded that the depletion of inositols by these drugs is not a coincidence — it’s likely a central mechanism of action [2].
The same review noted that this depletion in peripheral tissues creates a cascade of problems: disrupted thyroid function (hypothyroidism is a well-documented side effect of lithium), impaired glucose and lipid metabolism, weight gain, and cardiovascular effects. All of these conditions, the authors note, are also known to occur when inositol levels are depleted for other reasons — such as in polycystic ovary syndrome (PCOS) [2].
This dual insight — that inositol depletion might simultaneously explain why the drugs *work* and why they *harm* — is what has driven interest in inositol supplementation as an adjunct to mood stabiliser therapy. The logic being: could you top up peripheral inositol (reducing side effects) without raising central inositol high enough to undermine the therapeutic effect?
Evidence grade: Promising — one small pilot study (n=15), 6 months duration, no control group. Encouraging but preliminary.
A 2022 pilot study published in *European Review for Medical and Pharmacological Sciences* enrolled 15 patients over 18 years of age who were taking lithium and/or valproic acid for bipolar disorder [1]. Each participant took 4 grams per day of inositol — specifically 2 grams twice daily of a combined myo-inositol and d-chiro-inositol formula in the 80:1 ratio, alongside 50mg of alpha-lactalbumin (a protein that aids inositol absorption).
After six months, the primary finding was reassuring: no patients required changes or adjustments to their pharmacological therapy. In other words, the inositol supplementation did not appear to interfere with the mood-stabilising effects of their medication [1].
The secondary findings were genuinely encouraging: borderline thyroid function values improved, and markers of glucose and lipid metabolism moved in a positive direction — exactly the kinds of metabolic improvements you’d predict if peripheral inositol depletion was being corrected [1].
The authors concluded that 4 grams daily appears to be a safe supplementation dose for people on lithium or valproic acid. The 2021 review paper suggested this dose could be extended to 6 grams daily while still preserving the central therapeutic effect of lithium [2].
To be absolutely clear: this is a 15-person pilot study with no control group. It is not proof of efficacy. But as safety data goes — and safety is the critical question here — it is meaningfully reassuring, and the biological rationale is sound.
Evidence grade: Conflicted — small RCTs have produced inconsistent results, but “mostly negative” studies were underpowered and showed numerically positive trends.
A 2014 review in a peer-reviewed psychiatry journal assessed all randomised controlled trials of nutritional supplements in bipolar depression, and its verdict on inositol was nuanced rather than dismissive [7]. The review noted that “studies of inositol have been mostly negative, except for one study” — but crucially added that the negative studies were *underpowered* (too few participants to detect a real effect) and that they “demonstrated numerically positive effects for inositol.”
This is an important distinction. A study that fails to reach statistical significance because it enrolled 15 people is not the same as a study that enrolled 500 people and found nothing. When multiple small studies all point in the same direction but lack the statistical power to confirm it, that’s a signal worth paying attention to — even if it can’t yet be called evidence [7].
A 2013 literature review of complementary and alternative medicine in mood disorders was somewhat more positive, listing inositol among compounds that “are effective adjuncts in bipolar patients” alongside choline, 5-HTP, and N-acetylcysteine [9]. A 2011 review of second-tier natural antidepressants similarly concluded that inositol “may be useful in the treatment of bipolar depression when combined with mood stabilisers” [10].
A 1998 case report described a woman with chronic, treatment-resistant depression (dysthymic disorder) unresponsive to multiple antidepressants, who was given bupropion alongside inositol and ginkgo biloba as adjuncts. Her Hamilton Depression Rating Scale score dropped from 17 to 11, and her bupropion dose was reduced. The authors hypothesised that inositol was the probable active adjunct for the antidepressant effect [3]. One case report, of course, proves nothing — but it illustrates the direction of interest.
Why do the results conflict? The 2014 review offers some clues [7]: different studies used different doses, different patient populations (unipolar vs. bipolar), different durations, and different concomitant medications. Inositol may work better in some subgroups than others — particularly bipolar depression combined with mood stabilisers — and lumping all depression together may obscure a real signal in a specific population.
Evidence grade: Promising for the broader category, with varying strength for individual compounds.
It’s worth situating inositol within the wider research landscape on nutrition and mood disorders, because the context matters for understanding where it fits.
A 2023 review in *Current Opinion in Psychiatry* identified several nutraceuticals with clinical trial support for depression: omega-3, probiotics, zinc, saffron, curcumin, and St John’s wort [6]. Inositol was not among those with the strongest current endorsement for depression specifically, but the review noted that the field is still developing and that “further randomised controlled trials that take into consideration a number of emerging mechanisms, potential nutraceutical combinations and factors that may predict treatment response are required” [6].
A 2023 paper in *Brain Sciences* highlighted how mood disorders rarely occur in isolation — they frequently co-exist with obesity, hypertension, diabetes, and PCOS [8]. This is particularly relevant for inositol, because its metabolic benefits (especially in insulin sensitivity and thyroid function) mean that someone with bipolar disorder *and* metabolic dysfunction might benefit from multiple angles simultaneously — exactly the profile seen in the 2022 pilot study [1, 8].
The broader picture from multiple reviews is consistent: nutrition genuinely matters for brain health, supplementation can be a meaningful adjunct to standard treatment, and the evidence base is growing but still incomplete [6, 9, 15].
Let’s be honest about the gaps — and there are real ones.
The human trial data is thin. Most of the inositol-and-mood research involves small samples, short durations, and no control groups. The single largest source of optimism — the inositol depletion hypothesis — is well-supported mechanistically, but translating a mechanism into a proven clinical intervention requires much larger, well-designed RCTs that simply haven’t been done yet [7].
The “mostly negative” RCT record for depression is a genuine concern. The 2014 review was candid: clinical trials of inositol in bipolar depression have been “mostly negative” [7]. The charitable interpretation (underpowered studies, numerically positive trends) is plausible — but it remains an interpretation, not a confirmation.
We don’t know the optimal dose for mood. Studies have used varying doses. The safety data from the 2022 pilot suggests 4 grams daily is well-tolerated alongside mood stabilisers [1]. The 2021 review suggested up to 6 grams may preserve therapeutic efficacy while reducing side effects [2]. But for general mood support in people *not* on mood stabilisers, the optimal dose remains unclear.
Long-term data is lacking. The longest study reviewed here was six months [1]. We don’t know what happens with years of supplementation.
The interaction question cuts both ways. The central concern in research — whether inositol supplementation undermines the therapeutic effect of lithium or valproic acid by raising CNS inositol levels — has not been definitively resolved. The pilot study is reassuring [1], but 15 patients over six months cannot settle this question. Anyone on these medications should discuss supplementation with their prescriber.
Inositol’s role in unipolar depression (as opposed to bipolar) remains much less studied. Most of the positive signals come from bipolar contexts. The evidence for unipolar depression is even thinner.
So what does a sensible, informed person actually do with all of this?
First, let’s separate the two populations this research speaks to.
If you’re on lithium or valproic acid for bipolar disorder: The inositol research here is genuinely relevant to you. The biological rationale for why these drugs deplete inositol — and why that depletion may drive side effects — is well-supported [2, 12]. A small pilot study suggests 4 grams daily appears safe and may help with metabolic and thyroid side effects without undermining your medication [1]. This is worth raising with your psychiatrist or prescriber. Don’t supplement on your own without that conversation — not because inositol is dangerous, but because your medication management deserves a joined-up approach.
If you’re interested in inositol for general mood support or mild mood difficulties: The honest answer is that the evidence is interesting but not yet strong enough to make confident claims. The mechanistic picture is compelling, the safety profile looks good, and the direction of most studies — even the underpowered negative ones — points toward modest benefit in mood-related contexts [7, 9, 10]. Inositol is found naturally in fruits, beans, grains, and nuts, so supplementation is not introducing something foreign to your body.
Inositol is water-soluble, which means excess is excreted — it doesn’t accumulate in your tissues [10]. The safety profile at typical supplementation doses (2–4 grams daily) appears good across the research reviewed here. This is not a compound that demands cautious restraint in the way that fat-soluble vitamins do.
Some practical thinking:
– If you have bipolar disorder and experience side effects from lithium or valproic acid — particularly metabolic or thyroid-related ones — the inositol research is directly relevant to you. Bring the 2022 pilot study [1] and 2021 review [2] to your next appointment. – If you’re interested in mood support more generally, inositol’s risk/benefit profile is favourable enough that a daily dose of 2–4 grams is a reasonable consideration — particularly given that most people’s dietary intake has declined as processed food consumption has risen. – The 80:1 myo-inositol to d-chiro-inositol ratio used in the clinical studies appears to reflect the body’s natural balance and is the formulation to look for [1, 2]. – Don’t expect dramatic results. The research suggests modest, adjunctive benefit — not a standalone mood cure.
The story of inositol is, ultimately, one of a genuinely interesting biological mechanism that hasn’t yet received the large-scale human trial attention it deserves. The research we have is encouraging, the safety profile is reassuring, and the science behind it is some of the most intellectually compelling in the whole field of nutritional psychiatry. Watch this space — and in the meantime, the evidence is good enough to make inositol worth considering as part of a thoughtful, well-rounded approach to brain health.
[1] No Title Available (2022). Pilot study on myo-inositol and d-chiro-inositol supplementation in patients taking lithium and/or valproic acid. *European Review for Medical and Pharmacological Sciences*. DOI: 10.26355/eurrev_202210_29920 | https://pubmed.ncbi.nlm.nih.gov/36263538/
[2] No Title Available (2021). Review: inositol depletion, side effects of mood stabilisers, and the rationale for supplementation in bipolar disorder. *European Review for Medical and Pharmacological Sciences*. DOI: 10.26355/eurrev_202109_26657 | https://pubmed.ncbi.nlm.nih.gov/34533796/
[3] Inositol and Ginkgo biloba as Adjuncts in Chronic Depression: Case Report (1998). https://pubmed.ncbi.nlm.nih.gov/27414700/
[4] No Title Available (2026). Keywords: INM1, INO1, myo-inositol, bipolar disorder, docosahexaenoic acid, omega-3 fatty acids. DOI: 10.1007/s43440-025-00815-5 | https://pubmed.ncbi.nlm.nih.gov/41489728/
[5] No Title Available (2022). Mood disorders, folate, vitamin B12 and SAMe. *European Review for Medical and Pharmacological Sciences*. DOI: 10.26355/eurrev_202204_28479 | https://pubmed.ncbi.nlm.nih.gov/35442500/
[6] Nutraceuticals in mood disorders: current knowledge and future directions (2023). *Current Opinion in Psychiatry*. DOI: 10.1097/YCO.0000000000000826 | https://pubmed.ncbi.nlm.nih.gov/36044293/
[7] Review of nutritional supplements for the treatment of bipolar depression (2014). https://pubmed.ncbi.nlm.nih.gov/24353094/
[8] No Title Available (2023). Nutraceuticals, mood disorders and comorbidities. *Brain Sciences*. DOI: 10.3390/brainsci13091262 | https://pubmed.ncbi.nlm.nih.gov/37759862/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526332/
[9] Mood disorders and complementary and alternative medicine: a literature review (2013). https://pubmed.ncbi.nlm.nih.gov/23700366/
[10] Second-tier natural antidepressants: review and critique (2011). *Journal of Affective Disorders*. DOI: 10.1016/j.jad.2010.06.010 | https://pubmed.ncbi.nlm.nih.gov/20579741/
[11] No Title Available (2016). Randomised placebo-controlled trial: multivitamin supplementation, serotonin and mood. https://pubmed.ncbi.nlm.nih.gov/26994381/
[12] Yeast bioassay for identification of inositol depleting compounds (2009). https://pubmed.ncbi.nlm.nih.gov/18979283/
[13] No Title Available (2021). Systematic review and meta-analysis: vitamin C supplementation and mood. *General Hospital Psychiatry*. DOI: 10.1016/j.genhosppsych.2021.04.006 | https://pubmed.ncbi.nlm.nih.gov/33932734/
[14] Nutritional supplements in depressive disorders (2017). https://pubmed.ncbi.nlm.nih.gov/29171639/
[15] No Title Available (2020). Dietary strategies and supplements for mood and cognition: a review. DOI: 10.1007/s13668-020-00340-2 | https://pubmed.ncbi.nlm.nih.gov/33170436/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
